Forman Mark S 4
4 · Ventyx Biosciences, Inc. · Filed May 16, 2025
Insider Transaction Report
Form 4
Forman Mark S
Chief Medical Officer
Transactions
- Award
Common Stock
2025-05-15$1.03/sh+3,000$3,090→ 3,000 total
Footnotes (3)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"), for the ESPP Purchase Period (as defined in the 2021 ESPP) of November 15, 2024 through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).
- [F2]The relevant Offering Period (as defined in the 2021 ESPP) ended, and the shares were acquired, on the Exercise Date (as defined in the 2021 ESPP) of May 15, 2025.
- [F3]In accordance with the 2021 ESPP, these shares were purchased based on 85% of the closing price on May 15, 2025.